Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention

Novo NordiskNew research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.(1) Researchers linked factors such as food traditions and traditional gender roles to increasing vulnerability to diabetes in cities(1), where three-quarters of people with the disease are set to live by 2045.(3) The findings from the Cities Changing Diabetes research were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.

"For many years, diabetes has continued to rise at an alarming rate despite the best efforts of policymaker and healthcare providers," says David Napier, professor of Medical Anthropology at University College London (UCL). "In order to turn the table on this devastating and costly disease, we need to think differently and adopt new approaches. When public health strategies and individual care plans take into account the prevailing local cultures and associated conventions and behaviours, they are much more likely to be successful."

Fuelled by rapidly increasing rates of obesity, diabetes could affect one in nine adults by 2045 - more than 730 million people.(2) Within the same time frame, annual diabetes-related healthcare costs are expected to increase by 39% from 775 billion US dollars to more than 1 trillion dollars, further highlighting the urgency for action.(4)

Within their findings, researchers pointed to a number of social and cultural factors contributing to the rise of diabetes in cities around the world, including:(1)

  • In Copenhagen, standard medical referral practices acting as barriers to preventive care and services for diabetes
  • In Houston, food traditions becoming entwined with heritage and culture and often being perceived as providing 'comfort'
  • In Mexico City, traditional gender roles limiting effective self-care in male-only households, as some men are unable or unwilling to provide diabetes support to others

A second study presented by Cities Changing Diabetes researchers at EASD 2018 demonstrated that rates of diabetes and obesity are accelerating in every region of the world today. North America and Europe, where obesity has been rising for decades, are expected to have the highest future type 2 diabetes prevalence but also the slowest future increases.(5) Africa, on the other hand, is projected to see a near-threefold increase in the number of people living with diabetes as the population ages and obesity prevalence increases.(5) Achieving a 25% reduction of obesity prevalence on the continent would result in 15.3 million fewer people with type 2 diabetes in 2045.(5)

"Whether it's by initiating door-to-door care provision, relocating clinics within urban communities or through enabling peer support among religious faith groups, the many partners in the Cities Changing Diabetes programme are already acting to great effect on these research findings," said Niels Lund, vice president for Health Advocacy, Novo Nordisk. "However, halting the rise of diabetes requires others to learn from their approach and to develop strategies that reflect local needs. To this end, the Cities Changing Diabetes programme is an open and inclusive partnership in which anyone with a stake in the prevention and treatment of diabetes is welcome to participate."

About the studies

The first study carried out Vulnerability Assessments in five highly diverse cities - Copenhagen, Houston, Mexico City, Shanghai and Tianjin - to assess the impact of cultural factors on vulnerability to type 2 diabetes. This included traditions and conventions, health beliefs and food practices, gender attitudes, and local practices to care seeking. Using semi-structured interviews, assessments were conducted with a total of 740 people.(1)

The second study investigated the regional prevalence of type 2 diabetes from 2017-2045, using past and target trend scenarios. The past trend scenario assumes that future increase in obesity prevalence is extrapolated linearly, and in a target scenario obesity prevalence is reduced by 25% in 2045. BMI data for all countries worldwide 2000-2014 were obtained from the Non-communicable Disease Risk Factor Collaboration, and the share of people in each age and BMI class were projected depending on scenario.(5)

About Cities Changing Diabetes

Cities Changing Diabetes is a first-of-its-kind partnership programme with an ambitious global goal to reduce obesity by 25% so that only 1 in 10 people live with diabetes by 2045. More than 100 local partners - including city leaders and ministries, academia, diabetes associations, health insurers, community groups and business corporations - collaborate across disciplines and in new forms of public-private partnerships to map the diabetes problem, share solutions and drive actions to bend the curve on urban diabetes.

The programme was initiated in 2014 by three global partners: University College London, Steno Diabetes Center Copenhagen and Novo Nordisk. Today, 17 cities representing more than 130 million citizens are active partners: Beijing, Beirut, Buenos Aires, Copenhagen, Hangzhou, Houston, Jakarta, Johannesburg, Koriyama, Leicester, Mérida, Mexico City, Rome, Shanghai, Tianjin, Vancouver and Xiamen.

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.

1. Volkmann A-M, Hesseldal L, Bagger M, et al. Local traditions and conventions impact vulnerability to type 2 diabetes. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.
2. Moses A, Lund N, Jensen BB, et al. Illustrating the pivotal role of obesity as a driver of diabetes. Abstract presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria; 23-26 May 2018.
3. International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation; 2015.
4. Cities Changing Diabetes. Diabetes Projection Model, Global. Data on file. Novo Nordisk. In: Incentive, ed. Holte, Denmark; 2017.
5. Nielsen S, Napier D, Jensen BB, et al. Regional burden of obesity and diabetes in adults - projections from 2017-2045. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...